Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report

被引：0

作者：

Wang, W. ^{[1
]}

Xu, C. ^{[2
]}

Zhu, Y. ^{[3
]}

Liao, X. ^{[4
]}

Zhuang, W. ^{[5
]}

Du, K. ^{[3
]}

Chen, R. ^{[6
]}

Chen, Y. ^{[2
]}

Chen, G. ^{[2
]}

Fang, M. ^{[1
]}

机构：

[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China

[2] Fujian Prov Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China

[3] Zhejiang Rongjun Hosp, Chest Dis Diag & Treatment Ctr, Jiaxing, Peoples R China

[4] Zhejiang Rongjun Hosp, Tumor Mol Lab, Jiaxing, Peoples R China

[5] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China

[6] Geneplus Beijing, Beijing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

crizotinib; Resistance; small-cell lung cancer;

D O I：

10.1016/j.jtho.2017.09.1548

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02-018

引用

页码：S2244 / S2244

页数：1

共 50 条

[41] ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report
Chuang, Xin
Chen, Ying
Yu, Ping
Qiu, Xueshan
Wang, Jian
Qu, Xiujuan
Teng, Yuee
Liu, Yunpeng
Jin, Bo
THORACIC CANCER, 2018, 9 (11) : 1513 - 1518
[42] Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review
Li, Yalun
Zhang, Rui
Zhou, Yongzhao
Song, Juan
Luo, Wenxin
Tian, Panwen
Li, Weimin
CLINICAL LUNG CANCER, 2019, 20 (03) : E251 - E255
[43] Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
Fan, Jun
Wu, Junhua
Huang, Bo
Zhu, Yili
Shi, Heshui
Dai, Xiaofang
Nie, Xiu
DIAGNOSTIC PATHOLOGY, 2020, 15 (01)
[44] Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
Jun Fan
Junhua Wu
Bo Huang
Yili Zhu
Heshui Shi
Xiaofang Dai
Xiu Nie
Diagnostic Pathology, 15
[45] ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report
Gonzalez-Mosquera, Luis F.
Abu Rous, Fawzi
Rogers, Alexandra
Smith, Nicolina
Goyert, Gregory
Gadgeel, Shirish
CLINICAL LUNG CANCER, 2024, 25 (02) : e77 - e80
[46] TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib
Wang, Wen-Xian
Xu, Chun-Wei
Chen, Yan-Ping
Liu, Wei
Zhong, Li-Hua
Chen, Fang-Fang
Zhuang, Wu
Huang, Yun-Jian
Huang, Zhang-Zhou
Chen, Rong-Rong
Guan, Yan-Fang
Yi, Xin
Lv, Tang-Feng
Zhu, Wei-Feng
Lu, Jian-Ping
Wang, Xiao-Jiang
Shi, Yi
Lin, Xian-Dong
Chen, Gang
Song, Yong
JOURNAL OF THORACIC DISEASE, 2018, 10 (05) : 2991 - 2998
[47] TP53 Mutations Predict for Poor Survival in ALK Rearrangement Lung Adenocarcinoma Patients Treated with Crizotinib
Wang, W.
Xu, C.
Chen, Y.
Zhuang, W.
Lin, G.
Chen, X.
Wu, B.
Huang, Y.
Chen, R.
Guan, Y.
Yi, X.
Fang, M.
Lv, T.
Chen, G.
Song, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[48] Combined small cell lung carcinoma harboring ALK rearrangement: A case report and literature review
Niitsu, Takayuki
Shiroyama, Takayuki
Miyake, Kotaro
Noda, Yoshimi
Kido, Kansuke
Hara, Reina
Enomoto, Takatoshi
Adachi, Yuichi
Amiya, Saori
Suga, Yasuhiko
Fukushima, Kiyoharu
Koyama, Shohei
Iwahori, Kota
Hirata, Haruhiko
Nagatomo, Izumi
Takeda, Yoshito
Kumanogoh, Atsushi
THORACIC CANCER, 2020, 11 (12) : 3625 - 3630
[49] Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
Gao, Peng
Tang, Kangning
Hao, Yuqiu
Li, Wei
Lv, Xuejiao
Li, Dapeng
Jia, Yuxi
FRONTIERS IN ONCOLOGY, 2022, 12
[50] AfatinibRash and acquired resistance in lung adenocarcinoma: case report
Reactions Weekly, 2018, 1708 (1) : 27 - 27

← 1 2 3 4 5 →